Precision Radiotherapy, SBRT, Shows Promise as 1st Treatment for Low- and Medium-Risk Prostate Cancers

Precision Radiotherapy, SBRT, Shows Promise as 1st Treatment for Low- and Medium-Risk Prostate Cancers
Men newly diagnosed with low- or intermediate-risk prostate cancer may benefit more by being treated with high-dose stereotactic body radiotherapy (SBRT) as a first therapy than with other available radiotherapies, according to the results of a large and multi-center clinical trial. The data, recently announced at the 58th Annual Meeting of the American Society for Radiation Oncology (ASTRO) in a presentation titled "Five-Year Outcomes from a Multi-Center Trial of Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer," revealed that SBRT has shorter treatment duration, lower severe toxicity, and excellent cancer control rates. Usually, prostate tumors respond well to radiation therapy, but the possibility of radiation exposure to healthy tissue of the gastrointestinal (GI) and genitourinary (GU) tracts is a matter of concern to physicians. SBRT is an advanced technique designed to deliver high doses of radiation therapy to the tumor in few fractioned radiation treatments (usually up to five), with a high specificity to the tumor site. A specially designed coordinate-system is used to detect the exact localization of the tumors in the body, helping to avoid treating healthy tissue nearby and reducing toxicity to non-cancerous cells. Given its focused radiation delivery, this technique is now a standard of care for many patients with non-surgical lung cancer, working to prevent unnecessary radiation exposure to the heart and surrounding lung tissue. In prostate cancer patients, similarly, it can be used to avoid exposure to the adjacent bladder,
Subscribe or to access all post and page content.

One comment

Leave a Comment

Your email address will not be published. Required fields are marked *